Invitae Corporation, San Francisco, CA 94103, USA.
Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
Mol Genet Metab. 2023 Nov;140(3):107668. doi: 10.1016/j.ymgme.2023.107668. Epub 2023 Jul 26.
Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency (VLCADD) is a relatively common inborn error of metabolism, but due to difficulty in accurately predicting affected status through newborn screening, molecular confirmation of the causative variants by sequencing of the ACADVL gene is necessary. Although the ACMG/AMP guidelines have helped standardize variant classification, ACADVL variant classification remains disparate due to a phenotype that can be nonspecific, the possibility of variants that produce late-onset disease, and relatively high carrier frequency, amongst other challenges. Therefore, an ACADVL-specific variant curation expert panel (VCEP) was created to facilitate the specification of the ACMG/AMP guidelines for VLCADD. We expect these guidelines to help streamline, increase concordance, and expedite the classification of ACADVL variants.
长链酰基辅酶 A 脱氢酶(VLCAD)缺乏症(VLCADD)是一种相对常见的先天性代谢缺陷,但由于新生儿筛查难以准确预测受影响的状态,因此需要通过 ACADVL 基因的测序来确定致病变异的分子确证。尽管 ACMG/AMP 指南有助于规范变异分类,但由于表型可能不特异、存在导致迟发性疾病的变异的可能性以及相对较高的携带频率等挑战,ACADVL 变异分类仍然存在差异。因此,创建了一个专门的 ACADVL 变异管理专家小组(VCEP),以促进 VLCADD 中 ACMG/AMP 指南的具体规定。我们期望这些指南能够帮助简化、提高一致性,并加速 ACADVL 变异的分类。